The RegoMel trial
Presented by Dr Iris Dirven and Prof Bart Neyns (University Hospital of Brussels, Belgium)
Dr Iris Dirven, a medical oncologist in training, and Prof Bart Neyns, a medical oncologist at the University Hospital of Brussels, reported promising results from their research in the RegoMel trial, a phase II study evaluating the efficacy of regorafenib in patients with advanced pretreated melanoma.
References:
Dirven I, ASCO2024 #302
